What is Gamida Cell?
Gamida Cell, founded in 1998 and headquartered in Boston, MA, is a clinical-stage biopharmaceutical company dedicated to developing potentially curative cell therapies for blood cancers and serious blood diseases. The company's focus on novel therapeutic approaches positions it within the rapidly evolving field of oncology and hematology.
How much funding has Gamida Cell raised?
Gamida Cell has raised a total of $100M across 2 funding rounds:
Debt
$75M
Debt
$25M
Debt (2021): $75M with participation from Highbridge Capital Management
Debt (2022): $25M led by Highbridge Capital Management
Key Investors in Gamida Cell
Highbridge Capital Management
Highbridge Capital Management is a global alternative investment firm based in New York, known for its hedge fund strategy services and liquidity products. Their involvement suggests a focus on debt financing for established clinical-stage companies.
What's next for Gamida Cell?
The recent major strategic investment signals a critical phase for Gamida Cell, likely enabling the acceleration of its clinical development pipeline and the scaling of its manufacturing capabilities. This capital infusion is expected to support the company's efforts to bring its advanced cell therapies closer to market, addressing unmet needs in severe blood disorders and hematologic malignancies. The company's trajectory suggests a strong focus on regulatory milestones and potential commercialization.
See full Gamida Cell company page
